HighTower Advisors LLC Buys 20,302 Shares of Option Care Health, Inc. $OPCH

HighTower Advisors LLC lifted its position in Option Care Health, Inc. (NASDAQ:OPCH) by 4.9% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 436,147 shares of the company’s stock after acquiring an additional 20,302 shares during the quarter. HighTower Advisors LLC owned approximately 0.27% of Option Care Health worth $12,107,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds also recently made changes to their positions in OPCH. Cornerstone Planning Group LLC boosted its holdings in Option Care Health by 7,621.4% during the third quarter. Cornerstone Planning Group LLC now owns 1,081 shares of the company’s stock worth $30,000 after purchasing an additional 1,067 shares during the last quarter. McIlrath & Eck LLC bought a new position in shares of Option Care Health during the 2nd quarter worth approximately $37,000. Hantz Financial Services Inc. lifted its position in shares of Option Care Health by 987.7% during the 3rd quarter. Hantz Financial Services Inc. now owns 1,414 shares of the company’s stock worth $39,000 after buying an additional 1,284 shares in the last quarter. Elevation Point Wealth Partners LLC purchased a new position in shares of Option Care Health in the 2nd quarter worth approximately $40,000. Finally, EverSource Wealth Advisors LLC grew its holdings in shares of Option Care Health by 528.1% in the second quarter. EverSource Wealth Advisors LLC now owns 1,407 shares of the company’s stock valued at $46,000 after acquiring an additional 1,183 shares in the last quarter. Hedge funds and other institutional investors own 98.05% of the company’s stock.

Wall Street Analyst Weigh In

A number of analysts recently commented on the company. Citizens Jmp reiterated a “market outperform” rating and set a $38.00 price target (up from $36.00) on shares of Option Care Health in a report on Tuesday, January 13th. Barrington Research lifted their target price on Option Care Health from $38.00 to $42.00 and gave the stock an “outperform” rating in a research note on Friday, January 16th. Stephens upgraded shares of Option Care Health to a “strong-buy” rating in a research report on Thursday, December 11th. Morgan Stanley raised their price objective on shares of Option Care Health from $35.00 to $38.00 and gave the stock an “overweight” rating in a report on Tuesday, January 13th. Finally, Weiss Ratings reiterated a “hold (c)” rating on shares of Option Care Health in a research note on Monday, December 29th. One investment analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating and two have assigned a Hold rating to the company. Based on data from MarketBeat.com, Option Care Health presently has an average rating of “Moderate Buy” and a consensus price target of $37.58.

Option Care Health Price Performance

OPCH opened at $35.69 on Friday. The firm has a 50-day moving average price of $33.92 and a 200-day moving average price of $30.38. Option Care Health, Inc. has a twelve month low of $24.24 and a twelve month high of $36.80. The company has a quick ratio of 1.05, a current ratio of 1.56 and a debt-to-equity ratio of 0.85. The company has a market capitalization of $5.67 billion, a price-to-earnings ratio of 28.33, a PEG ratio of 2.13 and a beta of 0.84.

Option Care Health Company Profile

Option Care Health (NASDAQ: OPCH) is a leading provider of home and alternate site infusion services in the United States. The company specializes in the administration of injectable therapies, including antibiotics, nutrition, hydration, immunoglobulin, pain management and specialty pharmaceuticals. Through its nationwide network of infusion pharmacies and nursing professionals, Option Care Health delivers customized care plans and in-home nursing visits to patients managing complex or chronic conditions outside of a hospital setting.

Option Care Health traces its current structure to the completion of its merger with BioScrip in early 2021, combining two of the industry’s most experienced home infusion businesses.